Search clinical trials for: COPD, QAB149, QVA149, indacaterol maleate, gylcopyrronium bromide

Total 902 results

Novartis Pharmaceuticals

Completed

A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

United States, Romania, Hungary, Bulgaria, Spain, Finland, Puerto Rico
Novartis Pharmaceuticals

Completed

Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BEACON)

Chronic Obstructive Pulmonary Disease

Netherlands, Austria, Denmark, Norway, Sweden
Novartis Pharmaceuticals

Completed

Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

Colombia, India, Korea, Republic of, Poland, Croatia, Estonia, Hungary, United Kingdom, Israel, Latvia, Turkey, Argentina, Panama, Mexico, Russian Federation, Serbia, Slovenia
Novartis Pharmaceuticals

Completed

A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

Chronic Obstructive Pulmonary Disease (COPD)

United States, Poland, Romania, Canada, Philippines, Spain, Ukraine, Vietnam
Novartis Pharmaceuticals

Completed

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

United States, Colombia, Egypt, Hungary, France, Guatemala, Panama, Slovakia, Slovenia
Novartis Pharmaceuticals

Completed

Effect of Indacaterol on Inspiratory Capacity (IC)

Chronic Obstructive Pulmonary Disease

Germany
Novartis

Completed

Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Belgium, Netherlands, Canada, United States
Novartis Pharmaceuticals

Completed

Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD (INHALE)

Chronic Obstructive Pulmonary Disease

United Kingdom
Novartis Pharmaceuticals

Completed

Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
Novartis Pharmaceuticals

Withdrawn

A Study to Evaluate the Effects of Indacaterol Maleate (QAB149) as a New Formulation in the EPIC Test Fixture

Asthma
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma

Asthma

South Africa, Belgium, Croatia, Turkey, Hungary, Colombia, Slovakia, Philippines, Russian Federation, Guatemala, Germany
Novartis

Completed

Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function

Hepatic Insufficiency

United States
Novartis Pharmaceuticals

Completed

Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Belgium, Poland, Romania, Croatia, Estonia, Netherlands, Slovakia, Latvia, Lithuania, United Kingdom, Argentina, Bulgaria, Serbia, Austria, Hungary, Spain, Greece, Canada, Denmark, Czechia
Novartis Pharmaceuticals

Completed

A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device

Asthma

Germany, United Kingdom
Novartis Pharmaceuticals

Completed

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

Asthma

Germany, Spain, United States, Turkey, Canada, Hungary, Slovakia, Italy, Argentina, Czech Republic, France, Peru
Novartis Pharmaceuticals

Completed

A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients

COPD

Korea, Republic of
Novartis Pharmaceuticals

Completed

QVA Mechanistic Efficacy Study (Receptor Effects, Etc)

Chronic Obstructive Pulmonary Disease

United Kingdom
Novartis Pharmaceuticals

Completed

Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD. (MOVE)

Chronic Obstructive Pulmonary Disease

Germany
Novartis

Completed

Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

France, Germany, Belgium, Spain, Turkey, Italy, Canada, Australia
Novartis

Completed

Effect of Indacaterol on Inspiratory Capacity and Lung Function in Patients With COPD Versus Placebo and Formoterol

COPD

United Kingdom
Novartis Pharmaceuticals

Completed

Long Term Safety Study of NVA237 vs QAB149 in COPD Patients

Chronic Obstructive Pulmonary Disease (COPD)

United States
Novartis Pharmaceuticals

Completed

The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (BLAZE)

Chronic Obstructive Pulmonary Disease

Germany, Belgium, Spain, Canada, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices

Asthma

Germany, Netherlands, United Kingdom
Novartis Pharmaceuticals

Completed

Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients (CLAIM)

Chronic Obstructive Pulmonary Disease, COPD

Germany
Novartis

Completed

Evaluation of Pharmacokinetic Interaction of Indacaterol With Ketoconazole in Healthy Adult Subjects

Healthy

India
Novartis Pharmaceuticals

Completed

Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study) (POWER)

Chronic Obstructive Pulmonary Disease

Canada
Novartis Pharmaceuticals

Completed

Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Japan
Novartis Pharmaceuticals

Completed

QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) (ILLUMINATE)

Chronic Obstructive Pulmonary Disease (COPD)

Spain, Germany, Estonia, Hungary, Belgium, Czech Republic, Norway, Korea, Republic of, Lithuania
Novartis Pharmaceuticals

Completed

A Study to Assess the Long-term Safety of QVA149 (ENLIGHTEN)

Chronic Obstructive Pulmonary Disease

Romania, Lithuania, Canada, France, Hungary, India, South Africa, Korea, Republic of, Latvia, United Kingdom
Novartis Pharmaceuticals

Completed

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (SHINE)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Russian Federation, Taiwan, Canada, Germany, Philippines, South Africa, Spain, United Kingdom, Turkey, Hungary, Guatemala, Australia, Bulgaria, France, Poland, Switzerland, Slovakia, Japan
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.

Chronic Obstructive Pulmonary Disease

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of QVA149 in COPD Patients

Chronic Obstructive Pulmonary Disease

United States
Novartis Pharmaceuticals

Completed

Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations (SPARK)

Chronic Obstructive Pulmonary Disease

Germany, United States, Colombia, Poland, South Africa, Canada, Estonia, Hungary, India, Austria, Israel, Netherlands, United Kingdom, Argentina, France, Italy, Spain, Czech Republic, Denmark, Finland, Greece, Ireland, Mexico, Peru, Phi... and more
Novartis Pharmaceuticals

Completed

Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients (FAVOR)

Chronic Obstructive Pulmonary Disease | COPD

Germany
Novartis Pharmaceuticals

Completed

A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Sweden, Denmark, Norway
Novartis Pharmaceuticals

Completed

Dose Ranging Study for Indacaterol in Japanese Asthma Patients

Asthma

Japan
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen

COPD

Germany, Belgium, Poland, Romania, Italy, Spain, Estonia, Russian Federation, Austria, France, Slovakia, Czechia, Latvia, Lithuania, Greece, Hungary, United Kingdom, Portugal, Ireland, Norway, Slovenia, Denmark, Sweden
Novartis Pharmaceuticals

Completed

Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BRIGHT)

COPD

Germany, Spain
Novartis Pharmaceuticals

Completed

The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD) (QUANTIFY)

Chronic Obstructive Pulmonary Disease (COPD)

Germany
Novartis

Completed

Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Japan
Novartis Pharmaceuticals

Completed

QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Colombia, India, Korea, Republic of, Poland, Romania, South Africa, Italy, Austria, Belgium, Croatia, Estonia, Hungary, Russian Federation, Taiwan, Turkey, Japan, Spain, Sweden, United Kingdom, China, Thailand, Canada, Hong Kong and more
Novartis Pharmaceuticals

Withdrawn

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Chronic Obstructive Pulmonary Disease

Germany, Austria
Novartis Pharmaceuticals

Completed

Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma (QAB149)

Asthma

United States
Novartis Pharmaceuticals

Completed

Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Salts in Patients With Asthma

Asthma

Italy, Germany, France
Novartis Pharmaceuticals

Withdrawn

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Chronic Obstructive Pulmonary Disease

Colombia, India, Belgium, Argentina, Czech Republic
Novartis Pharmaceuticals

Completed

Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide. (SYNERGY)

Chronic Obstructive Pulmonary Disease: COPD

Switzerland
Novartis Pharmaceuticals

Completed

A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149

Chronic Obstructive Pulmonary Disease

China, Argentina, Taiwan, Chile
United Arab Emirates University
Tawam Hospital

Completed

Effects of Antioxidants and B Vitamins Supplements on Inflammation in Obese Diabetic Patients

Obesity | Diabetes
Novartis

Completed

Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Spain, France

3

Subscribe